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1396Background: Ischemic mitral regurgitation, a complication of myocardial infarction and coronary artery dis-
ease more generally, is associated with a high mortality rate and is estimated to affect 2.8 million Americans.
With 1-year mortality rates as high as 40%, recent practice guidelines of professional societies recommend re-
pair or replacement, but there remains a lack of conclusive evidence supporting either intervention. The choice
between therapeutic options is characterized by the trade-off between reduced operativemorbidity and mortality
with repair versus a better long-term correction of mitral insufficiency with replacement. The long-term benefits
of repair versus replacement remain unknown, which has led to significant variation in surgical practice.
Methods and Results: This article describes the design of a prospective randomized clinical trial to evaluate the
safety and effectiveness of mitral valve repair and replacement in patients with severe ischemic mitral regurgi-
tation. This trial is being conducted as part of the Cardiothoracic Surgical Trials Network. This article addresses
challenges in selecting a feasible primary end point, characterizing the target population (including the degree of
mitral regurgitation) and analytical challenges in this high mortality disease.
Conclusions: The article concludes by discussing the importance of information on functional status, survival,
neurocognition, quality of life, and cardiac physiology in therapeutic decision making. (J Thorac Cardiovasc
Surg 2012;143:1396-403)Ischemic mitral regurgitation (MR), especially severe is-
chemic MR, has long been associated with poor health out-
comes in patients with cardiac disease. Also known as
functional MR, ischemic MR is a complication of myocar-
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The Journal of Thoracic and Cardiovascular Sur2.8 million people in the United States in 2004.1 As the pop-
ulation ages and the survival after MI increases, so will the
number of people with ischemic MR.2 Ischemic MR is as-
sociated with a shortened survival. Even mild ischemic
MR after MI dramatically increases cardiovascular mortal-
ity, with a 17% increase at 3.5 years compared with that of
patients with similar degrees of ischemia but without MR
(29% vs 12%; P<.001).3 In a population with mixed levels
of severity of ischemic MR, overall mortality was 62% ver-
sus 39% in patients without MR (P< .001) at 5 years.4
When the ischemic MR was severe, the 1-year mortality
rate has been reported as being as high as 40%.5
Post-MI changes in ventricular structure and function can
produce MR through 2 distinct processes. Locally, inferior
and posterior remodeling can cause displacement of the
papillary muscles away from the mitral valve annulus, pro-
ducing leaflet tethering and restriction of motion. This in-
hibits the leaflets’ ability to close effectively at the level
of the annulus. Globally, annular enlargement owing to
left ventricular (LV) dilatation causes central malcoaptation
at the level of the annulus. This is compounded by LV dys-
function, which decreases the force available to close the
leaflets in opposition to the increased tethering forces noted
above.1,6,7
Revascularization does not often significantly reduce
moderate to severe MR; one study reported that moderate
to severe MR persisted in 77% of patients.8 Mitral valvegery c June 2012
Abbreviations and Acronyms
CTSN ¼ Cardiothoracic Surgical Trials
Network
EROa ¼ effective regurgitant orifice area
LV ¼ left ventricular
LVESVI ¼ left ventricular end-systolic volume
index
MI ¼ myocardial infarction
MR ¼ mitral regurgitation
NHLBI ¼ National Heart, Lung, and Blood
Institute
PI ¼ Principal Investigator
SF-12 ¼ short form health survey (12 items)
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However, suboptimal results were demonstrated, in part be-
cause the subvalvular apparatus was not being preserved.
Although repair and replacement both appear to eliminate
MR immediately postoperatively, large retrospective stud-
ies have suggested that repair has lower perioperative
mortality.9,10
The surgical approach to mitral valve repair has evolved
over time. Therapy directed to reducing the annular size
alone has a demonstrated 6-month recurrence of severe
MR of 28% to 30%.11,12 The long-term recurrence rates
are in the 72% range.11 Significant mitral annulus undersiz-
ing has been attempted; however, these long-term results
are still not optimal.13 Several new rings are available that
attempt to reshape the annulus. However, the major concern
remains that reduction annuloplasty alone does not address
the subvalvular changes or the tethering mechanism. Alter-
native surgical options have been explored, including extra-
ventricular Dacron patches and balloons14; external infarct
plication sutures15; reduction of leaflet tethering by cutting
a limited number of secondary chordae16,17; edge-to-edge
suture creating a double orifice valve18; LV restoration pro-
cedure with improvement of papillary muscle orientation19;
and suture relocation of the posterior papillary.20
Several studies thus have compared replacement and re-
pair in patients with severe MR, but considerable contro-
versy remains regarding the optimal surgical approach for
these patients. Available evidence is limited to observational
studies and case series, where correction for significant and
substantial imbalances in baseline patient characteristics (ie,
risk factors) is suboptimal. These studies are also limited by
short-term outcomemeasures, inclusion of patients with dif-
ferent types of mitral valve disease, and lack of information
on important secondary outcomes, such as quality of life.
Consequently, recent practice guidelines of professional so-
cieties recommend class I surgical treatment of patients with
symptomatic severe MR but do not indicate whether toThe Journal of Thoracic and Carrepair or replace the mitral valve inasmuch as the long-
term benefits of these alternative procedures are un-
known.21,22 The choice between therapeutic options is
characterized by a perceived trade-off between reduced op-
erative morbidity and mortality, with repair versus a poten-
tially better long-term correction of mitral insufficiency
with replacement. This uncertainty has led to significant var-
iations in surgical practice. Given the prevalence of this
high-mortality condition, a randomized trial that would ad-
dress the relative benefits of repair versus replacement in pa-
tients with severe ischemic MR could have a significant
impact on patient management and health outcomes.
This article describes the design of such a trial that is cur-
rently being conducted as part of the Cardiothoracic Surgi-
cal Trials Network (CTSN; Appendix 1) and funded by the
National Heart, Lung, and Blood Institute (NHLBI), the Na-
tional Institute for Neurological Diseases and Stroke, and
the Canadian Institute for Health Research. In particular,
the article addresses challenges in selecting a feasible pri-
mary end point, characterizing the target population (in-
cluding the degree of MR), and analytical challenges in
this high mortality disease. This article concludes by discus-
sing important insights that are expected to emerge from
this trial, which has already accrued over 50% of required
sample size.
STUDY DESIGN
The primary aim of the trial is to evaluate the impact of
replacement versus repair on LV remodeling, as assessed
by LV end-systolic volume index (LVESVI) at 12 months
after surgery. This is a parallel design, prospective, multi-
center, randomized (1:1) clinical trial comparing mitral
valve repair and mitral valve replacement (Figure 1). The
trial is conducted in highly experienced clinical centers par-
ticipating in the Cardiothoracic Surgery Clinical Trials
Network.
The randomization procedure is being performed intrao-
peratively, after the first incision and before cannulation of
the aorta. After verification of entry criteria, random treat-
ment assignment is generated by the trial’s electronic data
capture system. The randomization is stratified by clinical
center and uses a random permuted block design with
blocks of size 2, 4, and 6 to ensure balance in the number
of patients assigned to each treatment.
For the purpose of the primary analysis, patients are con-
sidered enrolled in the study once they are randomized and
an identification code is generated. All patients are to be fol-
lowed up for 24 months after randomization, and end points
are measured at 30 days and 6, 12, and 24 months. The na-
ture of the treatments precludes masking of patients and
their treating clinicians to treatment assignment; however,
all echocardiograms are being analyzed by an independent
core laboratory. Investigators will also be blinded to all data
from other clinical sites with the exception of serious,diovascular Surgery c Volume 143, Number 6 1397
Patients with Severe Ischemic MR (Per site echocardiographer)
Determination of Eligibility and Collection of Baseline Data
Random Assignment of Treatment
Mitral Ring Annuloplasty 
± CABG
(subvalvular procedure for 
severe tethering)
Mitral Valve Replacement 
± CABG
(complete subvalvular 
preservation)
Outcomes Measured at 1, 6, 12, and 24 months
Primary Outcome
LVESVI at 12 mos
Secondary Outcomes
Survival, Funct Status, QoL, 
Operative Measures, LOS, 
Readmission, MR, Remodeling, 
LVEF, Revasc, AE’s Cost
Data Analysis
FIGURE 1. Severe mitral regurgitation trial design schematic.MR,Mitral
regurgitation; CABG, coronary artery bypass grafting; LVESVI, left ven-
tricular end-systolic volume index; QoL, quality of life; LOS, length of
stay; LVEF, left ventricular ejection fraction; AEs, adverse events.
TABLE 1. Selected inclusion criteria
1. Chronic severe ischemic mitral regurgitation (often with tethering as
a major mechanism) in the judgment of the clinical site
echocardiographer, assessed by transthoracic echocardiogram.
Assessment of mitral regurgitation will be performed using an
integrative method.
2. Eligible for surgical repair and replacement of mitral valve
3. Coronary artery disease with or without the need for coronary
revascularization
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porting purposes. Trial oversight is provided by an indepen-
dent data safety and monitoring board.
CHARACTERIZATION OF PATIENT POPULATION
The patient population for this trial consists of patients
with severe ischemic MR (often with tethering as a major
mechanism) with and without the need for concomitant cor-
onary artery bypass surgery (Table 1). The degree of MR is
assessed by transthoracic echocardiogram, in the judgment
of the clinical site echocardiographer. Subsequently, all
echocardiograms are overread by the echocardiography
core laboratory. If site investigators have questions about
the degree or etiology of MR (ie, the presence and contribu-
tion of structural valve disease), echocardiograms can be
transmitted, via a secure Web-based system, for feedback
from the core laboratory before patient randomization.1398 The Journal of Thoracic and Cardiovascular SurInitially, the entry criteria established the degree of MR
based on assessment of effective regurgitant orifice area
(EROa) alone with severe MR defined as an EROa of 0.4
cm2 or more. However, screening efforts identified patients
with multiple quantitative echocardiographic indicators of
severe MR, who had an EROa of less than 0.4 cm2, who
were unable to be enrolled. In this ischemic population,
this was primarily observed in patients with eccentricity
of MR jets. As a result, the assessment of MR was modified
to the integrativemethod. If the EROa in a patient is found to
be less than 0.4 cm2, then additional assessments of the de-
gree of MR are guided by other color Doppler quantitative
methods (jet area/left atrial area ratio, vena contracta) and
supportive criteria in an integrated fashion (Appendix 2).
Because patients with MR owing to structural disease
have a different prognosis from that of those who have is-
chemic MR, such patients are excluded from entry. In addi-
tion, patients with poor operative risk owing to pulmonary
hypertension, severe renal disease, and hepatic disease are
also excluded from randomization. Selected exclusion cri-
teria are depicted in Table 2.
PRIMARY END POINTAND ANALYSIS
The primary end point for the trial is the degree of LV re-
modeling, as assessed by LVESVI at 12 months after inter-
vention by transthoracic echocardiogram. The null
hypothesis is that there is no difference in the postoperative
LVESVI between patients randomized to undergo mitral
valve repair compared with patients randomized to undergo
mitral valve replacement.
The primary null hypothesis will be tested in an intent-to-
treat analysis using a .05 level 2-tailed Wilcoxon rank sum
test. The choice of the Wilcoxon rank sum test for the pri-
mary analysis was motivated by the expectation of a rela-
tively substantial amount of nonignorable missing data,
primarily owing to patient mortality. One-year incidence
of mortality is expected to range from 15% to 20% and po-
tentially differ between randomization arms. Some patients,
expected to be few, may also be missing echocardiographic
assessment for reasons directly related to the severity of their
illness. These missing data cannot be considered ignorable,
and imputation requires strong untestable assumptions.
A number of additional secondary analyses are planned
to supplement the primary analysis and aid interpretationgery c June 2012
TABLE 2. Selected exclusion criteria
Selected exclusion criteria
1. Any evidence of structural mitral valve disease or ruptured papillary
muscle
2. Inability to derive effective regurgitant orifice area and end-systolic
volume index by transthoracic echocardiography
3. Planned concomitant intraoperative procedures (except tricuspid
valve repair, patent foramen ovale closure, atrial septal defect
closure, or maze procedure)
4. Prior mitral valve repair
5. Contraindications to cardiopulmonary bypass
6. Clinical signs of cardiogenic shock at the time of randomization
7. Treatment with chronic intravenous inotropic therapy at the time of
randomization
8. Severe irreversible pulmonary hypertension in the judgment of the
investigator
9. ST-segment elevation myocardial infarction requiring intervention
within 7 days before randomization
10. Congenital heart disease (except patent foramen ovale or atrial septal
defect)
11. Chronic renal insufficiency defined by creatine 2.5 or chronic renal
replacement therapy
12. Evidence of cirrhosis or hepatic synthetic failure
13. Excessive surgical risk (in the judgment of the surgical investigator)
14. Recent history of psychiatric disease that may impair compliance
with protocol
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analysis on the ranked differences of LVESVI from ran-
domization to 12 months and extending the Wilcoxon
rank sum test to adjust for baseline LVESVI (ie, a ‘‘nonpara-
metric analysis of covariance’’). Because this is a random-
ized trial, no baseline differences are expected. A secondary
analysis of the primary end point will also be performed by
jointly modeling LVESVI and time to death using a model
suggested by Xu and Zeger.23 This model uses a latent vari-
able approach, whereby conditional on this latent variable
LVESVI and time to death are assumed to be independent.
SAMPLE SIZE ESTIMATION
Sample size estimates to ensure the ability to detect, with
high probability, a clinically meaningful presumed benefit
for patients undergoing mitral valve repair were based on
data derived from the clinical literature.24-26 We assume
that the mean baseline LVESVI in the target population is
100 mL/m2. For patients randomized to receive mitral
valve repair, we anticipate a 20% reduction in LVESVI,
or an absolute change of 20 mL/m2. We believe
a meaningful effect worth detecting is an additional 15%
(15 mL/m2), or a total reduction of 35% or 35 mL/m2 for
patients undergoing mitral valve replacement. Assuming
that baseline and 12-month LVESVI in both arms follows
a gamma distribution with common standard deviation of
35 mL/m2, a total of 250 patients, randomized with equal
probability to each arm, provides approximately 90%The Journal of Thoracic and Carpower to detect a difference of 15 mL/m2. Power is based
on a .05 level 2-tailed Wilcoxon rank sum test. The sample
size takes account of a single interim analysis to be per-
formed in addition to the final analysis.
INTERIM ANALYSIS
We will perform a single interim analysis with respect to
the primary end point to give the option of stopping early
should results strongly favor one arm or the other. The pro-
posed timing of this analysis is at .5 on the information
scale, that is, after half of the patients (125) reach the pri-
mary end point. We will use the Lan-DeMets approach, im-
plementing an O’Brien-Fleming–type spending function
that allots most of the type I error to the final look. The re-
sulting critical values to be used for each analysis are 2.963
at the first interim analysis and 1.969 at the final analysis. In
addition to the ethical concern of continuing a trial that
shows a clear benefit in favor of one treatment, there is
also a corresponding ethical concern of continuing a trial
that has little chance of ever showing a benefit of one treat-
ment comparedwith the other. The trial’s conditional power,
under the original alternative hypothesis, will be computed
at the interim look, which will allow the data safety and
monitoring board to use this to determine whether random-
ization, if not completed, should be halted for futility.
CHARACTERIZATION OF TREATMENT
INTERVENTIONS
In designing this trial, the investigators spent consider-
able time specifying the guidelines that define the surgical
technique. These specifications include designation that
all procedures must be performed with full or partial ster-
notomy or with a right thoracotomy with cardiopulmonary
bypass according to local standards. Exposure of the mitral
valve is accomplished by either the left atrial (Waterston
groove) or biatrial approach.Mitral valve replacement is ac-
complished with complete chorda sparing. The technique
for subvalvular preservation, the type of prosthesis (me-
chanical or bioprosthesis), and technique of suture place-
ment are selected by the surgeon, at his or her preference.
Mitral valve repair is accomplished using an undersized an-
nuloplasty ring. The ring size is determined by the surface
area of the anterior mitral leaflet as measured by the inter-
trigonal distance and anterior leaflet height. A subvalvular
procedure can be performed if tethering is present. Second-
ary mitral valve replacement can be performed at the sur-
geon’s discretion if residual MR is significant after LV
saline infusion testing or at transesophageal echocardiogra-
phy after cardiopulmonary bypass. Coronary artery bypass
grafting is performed using standard techniques and 2-stage
venous cannulation. Conduit selection and harvesting
methods are not prescribed, although use of the left internal
thoracic artery is recommended when a graft to the left an-
terior descending coronary artery is indicated. Completediovascular Surgery c Volume 143, Number 6 1399
Acquired Cardiovascular Disease Perrault et al
A
C
Drevascularization should be accomplished, within the judg-
ment of the surgical investigator.
SECONDARY END POINTS
Mortality
All-cause mortality is a particularly important secondary
end point. Given that this trial’s primary end point is an
echocardiographic assessment (LVESVI), it will be impor-
tant to supplement the finding of a treatment effect (or lack
of one) for the primary end point with a corresponding ef-
fect on a clinical end point such as all-cause mortality.
The trial is not powered to detect small mortality differ-
ences; however, an observed difference in mortality, consis-
tent in direction with that observed for LVESVI, will serve
to validate the trial’s findings. The proportion of deaths be-
tween randomization groups, both at 12 and 24 months, will
be compared by a c2 test. Time to death will be described by
Kaplan-Meier curves and differences between randomiza-
tion groups assessed via the log–rank test.
Quality of Life, Functional Status, and
Neurocognition
Several measures of quality of life will be used to capture
both overall quality of life and disease-specific quality of
life. Overall quality of life will be captured with the short
form health survey (SF-12) and EuroQol, whereas disease-
specific quality of life will be measured with the Minnesota
Living with Heart Failure Score and the Duke Activity Sta-
tus Index. Measurements with these instruments will occur
at 30 days and at 6, 12, and 24 months. Functional status
will be captured through measurement of cardiopulmonary
stress testing, as clinically tolerated, New York Heart Asso-
ciation heart failure class, and the Canadian Cardiovascular
Society angina class at 6 and 12months after randomization.
Neurocognitive performance at 12 months will be assessed
using the following battery of tests: Hopkins Verbal Learn-
ing Test,27 Trail Making Tests A and B,28 Medical College
ofGeorgiaComplex Figures,29 BostonNaming Test,30 Digit
Span,31 and Digit Symbol Substitution Test.31
Adverse Events, Hospitalization, and Economic End
Points
Serious and protocol-defined adverse events are mea-
sured prospectively and differences between treatment
groups will be assessed using Poisson regression. In addi-
tion, major adverse cardiac events are being assessed. These
events are a nonweighted composite end point composed of
death, stroke, worsening heart failure (þ1 New York Heart
Association class), hospitalization for congestive heart
failure, and mitral valve reintervention. The proportion of
patients experiencing a major cardiac event will be com-
pared by c2 test at 12 and 24 months. Economic end points
are important as well. Hospital resource usewill be captured
by measuring overall length of stay and intensive care unit1400 The Journal of Thoracic and Cardiovascular Surdays during the index hospitalization, as well as readmission
rates for all causes and specifically for heart failure. Days
alive out of the hospital will be compared between treatment
groups accounting as a percent of survival. Hospital costs
will be calculated from hospital charges using the
institution-specific ratio of cost to charges. The incremental
cost-effectiveness ratio in units of dollars per quality-
adjusted life years will be calculated when the differences
in health outcomes are associated with a difference in cost.
DISCUSSION
Patients with severe ischemic MR constitute a large and
growing population with a dismal prognosis. Both mitral
valve repair and replacement procedures are widely used
to treat this problem. Yet, there is considerable controversy
over the relative benefits of these 2 treatment approaches
and no definitive trials to guide treatment decisions. The
CTSN identified this as a high-priority concern and chose
to address it as one of its first randomized trials. The
CTSN’s severe MR trial, which is in essence a comparative
effectiveness trial, is designed to provide insights into
a range of outcomes that are relevant to clinicians and pa-
tients for making treatment decisions and should expand
the methodology for conducting surgical trials.
Ideally, clinical trials should be powered to make defini-
tive statements about all of the relevant clinical end points.
However, providing adequate power for all of the relevant
clinical end points, including mortality, in the severe MR
trial would have required a sample size in the range of sev-
eral thousand patients. It would not have been feasible to en-
roll and complete follow-up for all patients and analyze and
disseminate the results of such a trial within the 5-year term
of the CTSN. As such, the CTSN investigators chose LV re-
modeling as the primary end point. Specific guidelines were
created for ensuring rigorous and standardizedmeasurement
of this end point, and an independent core laboratory was es-
tablished to overread all echocardiograms in this trial and
provide real time consultation to investigators during the en-
rollment process. Mortality is the most important secondary
end point and will provide corroborating evidence needed to
interpret the differences observed in ventricular remodeling.
A critical dimension for making treatment decisions is in-
formation about the expectations for quality of life after sur-
gery. Particularly relevant to this target population are the
impact of treatment on congestive heart failure and angina
pectoris symptoms. To measure treatment effects on conges-
tive heart failure symptoms and functional status, the trial is
measuring New York Heart Association classification, Min-
nesota Living with Heart Failure Score, the Duke Activity
Status index, and peak volume of oxygen use. Given that
one of the concerns about mitral valve repair is that it might
not be as effective as replacement in controllingMR, it is im-
portant that the impact of heart failure on quality of life and
functional status be measured longitudinally throughout thegery c June 2012
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general measures of quality of life (ie, the SF-12 and Euro-
Qol) will allow us to interpret the observed disease-specific
symptoms in the broader context of physical andmental qual-
ity of life experienced by patients. These health status
measures will also be used to calculate quality-adjusted
life-years for the cost-effectiveness analysis.
Another critical concern of patients undergoing cardiac
surgery is the impact of surgery on brain functioning.
This trial, therefore, has been designed to carefully measure
cognitive functioning and neurologic events over the 2-year
time period. An independent neurocognitive core laboratory
was established to train investigators in neurocognitive test-
ing, score all test results, and provide quality assurance rel-
ative to this measure throughout the trial. The investigators
are also exploring alternative methods for analyzing neuro-
cognitive data, which have the potential to address some of
the controversies regarding analysis in this field.
The severe ischemic MR trial has already enrolled over
half of the required patient population. The enrollment
rate has increased substantially over time, and completion
of enrollment is clearly within sight. The broad spectrum
of end points being captured in this trial should address
the current dilemmas in choosing an optimal surgical ap-
proach for this patient group and provide invaluable infor-
mation for clinicians and patients alike making this
treatment decision.References
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APPENDIX 2. Integrative method criteria for echo assessment of degree of MR
Echo color Doppler criteria
Mild Moderate Severe
Color flow jet area <20% of LA area 20% to 39% of LA area Large central jet (usually>10 cm2 or
>40% of LA area) or variable size
wall—impinging jet swirling in LA
Quantitative parameters
VC width (cm) <0.3 0.3-0.69 0.7
EROa (cm2) <0.20 0.20-0.29 0.30-0.39 0.40
Echo supportive criteria
Mild Moderate Severe
Structural Doppler parameters
LA size Normal Normal or dilated Usually dilated
LV size Normal Normal or dilated Usually dilated
Mitral leaflets or support
apparatus
Normal or abnormal Normal or abnormal Abnormal/flail leaflet/ ruptured
papillary muscle
Mitral inflow—PW Awave dominant Variable E wave dominant (E usually 1.2 m/s)
Jet density—CW Incomplete or faint Dense Dense
Jet contour—CW Parabolic Usually parabolic Early peaking—triangular
Pulmonary vein flow Systolic dominance Systolic blunting Systolic flow reversal
LA, Left atrium; VC, vena contracta; EROa, effective regurgitant orifice area; LV, left ventricular; PW, pulsed wave; CW, continuous wave.
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